Major contribution to the academic debate on the comparative utility of regulatory and liability systems, on public versus private enforcement, and on deterrence versus other forms of behaviour control.
Les informations fournies dans la section « Synopsis » peuvent faire référence à une autre édition de ce titre.
Sonia Macleod is Researcher in the Research Programme on Civil Justice Systems at the Centre for Socio-Legal Studies, University of Oxford, UK. She was the Lead Researcher for the Independent Medicines and Medical Devices Safety Review.
Sweta Chakraborty is a cognitive behavioural scientist, and most recently the Associate Director of the Institute of Science for Global Policy, Washington D.C. She is a former programme associate on pharmaceutical regulation and product liability at Oxford University's Centre for Socio-Legal Studies (CSLS) and an adjunct assistant professor at Columbia University. Prior to joining the ISGP, Dr. Chakraborty served as the resident cognitive behavioral scientist at Lootok Ltd., a risk management-consulting firm. She received her doctorate in Risk Management from King's College London and her undergraduate degrees are in Decision Science and International Relations from Carnegie Mellon University. Her primary area of expertise is in science and technology policy options for topics of international concern (e.g., emerging technologies, infectious disease, food/agriculture security, environment and climate issues). Her research has included studies of risk perception, risk and crisis communications, corporate reputational management, risk regulation, and public trust. She has applied quantitative and qualitative research methods developed in the fields of social and decision sciences to study irrational consumer behaviors and public reactions to perceived risks (e.g., GMOs, prescription drugs). She asserts that understanding public perceptions of risk is the necessary first step towards developing communications to address public concerns, recover from negative media backlash, and improve upon levels of public trust. Sweta has over 25 published articles, has contributed to 3 additional books, and is a co-author of the forthcoming book Pharmaceutical Safety: A Study in Public and Private Regulation.
Les informations fournies dans la section « A propos du livre » peuvent faire référence à une autre édition de ce titre.
Vendeur : HPB-Red, Dallas, TX, Etats-Unis
hardcover. Etat : Good. Connecting readers with great books since 1972! Used textbooks may not include companion materials such as access codes, etc. May have some wear or writing/highlighting. We ship orders daily and Customer Service is our top priority! N° de réf. du vendeur S_421981605
Quantité disponible : 1 disponible(s)
Vendeur : ICTBooks, Wichita, KS, Etats-Unis
Etat : new. N° de réf. du vendeur ICV.1509916695.N
Quantité disponible : 1 disponible(s)
Vendeur : HPB-Blue, Dallas, TX, Etats-Unis
hardcover. Etat : Fine. Connecting readers with great books since 1972! May contain remainder marks. We ship orders daily and Customer Service is our top priority! N° de réf. du vendeur D_00000000000010284141
Quantité disponible : 1 disponible(s)
Vendeur : Bookmarc's, La Porte, TX, Etats-Unis
Hardcover. Etat : Very Good. Etat de la jaquette : Very Good. First British Edition. Y2 - A first British edition hardcover book in very good condition in very good dust jacket that is mylar protected. Dust jacket has some wrinkling on the edges and corners, some scratches, dust jacket and book have some bumped corners, some wrinkling on the spine edges, light discoloration and shelf wear. Civil Justice Systerms, Series General Editor Christopher Hodges. 9.75"x6.75", 298 pages. Satisfaction Guaranteed. This book examines how regulatory and liability mechanisms have impacted upon product safety decisions in the pharmaceutical and medical devices sectors in Europe, the USA and beyond since the 1950s. Thirty-five case studies illustrate the interplay between the regulatory regimes and litigation. Observations from medical practice have been the overwhelming means of identifying post-marketing safety issues. Drug and device safety decisions have increasingly been taken by public regulators and companies within the framework of the comprehensive regulatory structure that has developed since the 1960s. In general, product liability cases have not identified or defined safety issues, and function merely as compensation mechanisms. This is unsurprising as the thresholds for these two systems differ considerably; regulatory action can be triggered by the possibility that a product might be harmful, whereas establishing liability in litigation requires proving that the product was actually harmful. As litigation normally post-dates regulatory implementation, the 'private enforcement' of public law has generally not occurred in these sectors. This has profound implications for the design of sectoral regulatory and liability regimes, including associated features such as extended liability law, class actions and contingency fees. This book forms a major contribution to the academic debate on the comparative utility of regulatory and liability systems, on public versus private enforcement, and on mechanisms of behaviour control. Size: 8vo - over 7¾" - 9¾" tall. N° de réf. du vendeur 2511ec1592
Quantité disponible : 1 disponible(s)
Vendeur : Basi6 International, Irving, TX, Etats-Unis
Etat : Brand New. New. US edition. Expediting shipping for all USA and Europe orders excluding PO Box. Excellent Customer Service. N° de réf. du vendeur ABEOCT25-168400
Quantité disponible : 1 disponible(s)
Vendeur : Majestic Books, Hounslow, Royaume-Uni
Etat : New. Print on Demand pp. 320. N° de réf. du vendeur 370743944
Quantité disponible : 4 disponible(s)
Vendeur : GreatBookPrices, Columbia, MD, Etats-Unis
Etat : New. N° de réf. du vendeur 30929528-n
Quantité disponible : Plus de 20 disponibles
Vendeur : GreatBookPrices, Columbia, MD, Etats-Unis
Etat : As New. Unread book in perfect condition. N° de réf. du vendeur 30929528
Quantité disponible : Plus de 20 disponibles
Vendeur : Biblios, Frankfurt am main, HESSE, Allemagne
Etat : New. PRINT ON DEMAND pp. 320. N° de réf. du vendeur 18376350045
Quantité disponible : 4 disponible(s)
Vendeur : Grand Eagle Retail, Bensenville, IL, Etats-Unis
Hardcover. Etat : new. Hardcover. This book examines how regulatory and liability mechanisms have impacted upon product safety decisions in the pharmaceutical and medical devices sectors in Europe, the USA and beyond since the 1950s. Thirty-five case studies illustrate the interplay between the regulatory regimes and litigation. Observations from medical practice have been the overwhelming means of identifying post-marketing safety issues. Drug and device safety decisions have increasingly been taken by public regulators and companies within the framework of the comprehensive regulatory structure that has developed since the 1960s. In general, product liability cases have not identified or defined safety issues, and function merely as compensation mechanisms. This is unsurprising as the thresholds for these two systems differ considerably; regulatory action can be triggered by the possibility that a product might be harmful, whereas establishing liability in litigation requires proving that the product was actually harmful. As litigation normally post-dates regulatory implementation, the private enforcement of public law has generally not occurred in these sectors. This has profound implications for the design of sectoral regulatory and liability regimes, including associated features such as extended liability law, class actions and contingency fees. This book forms a major contribution to the academic debate on the comparative utility of regulatory and liability systems, on public versus private enforcement, and on mechanisms of behaviour control. This item is printed on demand. Shipping may be from multiple locations in the US or from the UK, depending on stock availability. N° de réf. du vendeur 9781509916696
Quantité disponible : 1 disponible(s)